Drug Type Monoclonal antibody |
Synonyms 塔戈利单抗, A 167, A-167 + [4] |
Target |
Mechanism PDL1 inhibitors(Programmed death-ligand 1 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Nasopharyngeal Carcinoma | NDA/BLA | CN | 12 May 2024 | |
Metastatic HER2-Negative Breast Carcinoma | Phase 2 | CN | 17 Aug 2022 | |
Solid tumor | Phase 2 | US | 13 Sep 2021 | |
Lymphoma | Phase 2 | CN | 23 Sep 2019 | |
Classical Hodgkin's Lymphoma | Phase 2 | CN | 01 Aug 2018 | |
Hodgkin's Lymphoma | Phase 2 | - | 30 Jul 2018 | |
Refractory Classic Hodgkin Lymphoma | Phase 2 | CN | 17 Jul 2018 | |
Relapsing classical Hodgkin lymphoma | Phase 2 | CN | 17 Jul 2018 | |
B-Cell Lymphoma | Phase 1 | CN | 19 Sep 2018 | |
Extranodal NK-T-Cell Lymphoma | Phase 1 | CN | 19 Sep 2018 |
Phase 2 | Non-Small Cell Lung Cancer First line | 103 | ractbixmsk(bthvebqdat) = skupkzdber ywqwcmcpfx (edgojhbedh ) View more | Positive | 24 May 2024 | ||
ractbixmsk(bthvebqdat) = rhqtxpcgkc ywqwcmcpfx (edgojhbedh ) View more |